CN101031565B - 取代的2h-1,3-苯并噁嗪-4(3h)-酮 - Google Patents

取代的2h-1,3-苯并噁嗪-4(3h)-酮 Download PDF

Info

Publication number
CN101031565B
CN101031565B CN2005800328848A CN200580032884A CN101031565B CN 101031565 B CN101031565 B CN 101031565B CN 2005800328848 A CN2005800328848 A CN 2005800328848A CN 200580032884 A CN200580032884 A CN 200580032884A CN 101031565 B CN101031565 B CN 101031565B
Authority
CN
China
Prior art keywords
alkyl
compound
halogen
och
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800328848A
Other languages
English (en)
Chinese (zh)
Other versions
CN101031565A (zh
Inventor
罗伯特·M·斯卡伯勒
明纳卡什·S·文卡特拉曼
张晓明
安贾莉·潘迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN101031565A publication Critical patent/CN101031565A/zh
Application granted granted Critical
Publication of CN101031565B publication Critical patent/CN101031565B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2005800328848A 2004-09-29 2005-09-26 取代的2h-1,3-苯并噁嗪-4(3h)-酮 Expired - Fee Related CN101031565B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61456404P 2004-09-29 2004-09-29
US60/614,564 2004-09-29
PCT/US2005/034246 WO2006039212A2 (en) 2004-09-29 2005-09-26 Substituted 2h-1,3-benzoxazin-4(3h)-ones

Publications (2)

Publication Number Publication Date
CN101031565A CN101031565A (zh) 2007-09-05
CN101031565B true CN101031565B (zh) 2010-09-29

Family

ID=36142983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800328848A Expired - Fee Related CN101031565B (zh) 2004-09-29 2005-09-26 取代的2h-1,3-苯并噁嗪-4(3h)-酮

Country Status (13)

Country Link
US (1) US7205296B2 (https=)
EP (1) EP1812429A4 (https=)
JP (1) JP2008514703A (https=)
KR (1) KR20070064356A (https=)
CN (1) CN101031565B (https=)
AU (1) AU2005292314B2 (https=)
BR (1) BRPI0516181A (https=)
CA (1) CA2581638A1 (https=)
IL (1) IL182180A0 (https=)
MX (1) MX2007003836A (https=)
NZ (1) NZ554211A (https=)
WO (1) WO2006039212A2 (https=)
ZA (1) ZA200702688B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US7740693B2 (en) * 2007-10-01 2010-06-22 Honeywell International Inc. Organic fluorescent sulfonyl ureido benzoxazinone pigments
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
CN104718188B (zh) * 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
HK1213181A1 (zh) 2012-09-27 2016-06-30 Portola Pharmaceuticals, Inc. 雙環氧雜內酰胺激酶抑制劑
RU2015143906A (ru) 2013-03-14 2017-04-18 Дженентек, Инк. Замещенные триазолопиридины и способы их применения
BR112015023397A2 (pt) 2013-03-15 2017-07-18 Genentech Inc benzoxazois substituídos e métodos de uso dos mesmos
WO2015078374A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
SI3259253T1 (sl) 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
HK1252567A1 (zh) 2015-05-22 2019-05-31 基因泰克公司 被取代的苯甲酰胺和其使用方法
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
CA2999769A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
PE20190980A1 (es) 2016-10-17 2019-07-09 Genentech Inc Compuestos terapeuticos y metodos para utilizarlos
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
NZ760129A (en) 2017-07-07 2025-12-19 Inflazome Ltd Novel sulfonamide carboxamide compounds
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
UY37848A (es) 2017-08-15 2019-03-29 Inflazome Ltd Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
EP3720849A2 (en) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
EP4074707A4 (en) * 2019-12-10 2024-01-03 Shanghai Zhimeng Biopharma, Inc. COMPOUND WITH NEUROPROTECTIVE EFFECT, PREPARATION METHOD AND USE THEREOF
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099032A (zh) * 1993-03-08 1995-02-22 合成实验室公司 苯并噁嗪衍生物，其制备方法及其药用
US6166246A (en) * 1996-10-18 2000-12-26 Ihara Chemical Industry Co., Ltd. 4-fluorosalicyclic acid derivative and process for production thereof
WO2004052871A1 (ja) * 2002-12-06 2004-06-24 Toray Industries, Inc. ベンゾモルホリン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
JP2002509152A (ja) 1998-01-15 2002-03-26 シーオーアール セラピューティクス インコーポレイテッド 血小板ａｄｐ受容体阻害剤
CA2332608C (en) 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
US6509348B1 (en) 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
DK1257550T3 (da) 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
ES2282304T3 (es) 2000-11-01 2007-10-16 Astellas Pharma Inc. Procedimiento para seleccionar antiplaquetas.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
AU2004278030C1 (en) * 2003-10-03 2010-12-02 Portola Pharmaceuticals, Inc. 2,4-Dioxo-3-quinazolinylaryl sulfonylureas
JP4879745B2 (ja) * 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド 置換イソキノリノン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1099032A (zh) * 1993-03-08 1995-02-22 合成实验室公司 苯并噁嗪衍生物，其制备方法及其药用
US6166246A (en) * 1996-10-18 2000-12-26 Ihara Chemical Industry Co., Ltd. 4-fluorosalicyclic acid derivative and process for production thereof
WO2004052871A1 (ja) * 2002-12-06 2004-06-24 Toray Industries, Inc. ベンゾモルホリン誘導体

Also Published As

Publication number Publication date
IL182180A0 (en) 2007-07-24
NZ554211A (en) 2010-10-29
ZA200702688B (en) 2008-06-25
EP1812429A4 (en) 2010-07-21
JP2008514703A (ja) 2008-05-08
AU2005292314B2 (en) 2011-11-03
US20060069093A1 (en) 2006-03-30
CA2581638A1 (en) 2006-04-13
MX2007003836A (es) 2007-08-20
EP1812429A2 (en) 2007-08-01
WO2006039212A3 (en) 2007-01-25
BRPI0516181A (pt) 2008-08-26
US7205296B2 (en) 2007-04-17
CN101031565A (zh) 2007-09-05
AU2005292314A1 (en) 2006-04-13
KR20070064356A (ko) 2007-06-20
HK1111414A1 (en) 2008-08-08
WO2006039212A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
CN101031565B (zh) 取代的2h-1,3-苯并噁嗪-4(3h)-酮
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
JP5112423B2 (ja) ピリドピリミジノン誘導体
US8552015B2 (en) Quinazolinone derivatives and their use as CB agonists
IL174446A (en) 2,4-dioxo-3-quinazolinylaryl sulfonylurea derivatives and pharmaceutical compositions containing the same
JPH06507625A (ja) アンギオテンシンｉｉアンタゴニストとしての酸官能基を有する置換ピリミジノン
TW200402294A (en) Chemical compounds
CN1323076C (zh) 4,4－二氟－1,2,3,4－四氢－5h－1－苯并氮杂䓬衍生物或其盐
TW200902532A (en) Aza-pyridopyrimidinone derivatives
CN103974955B (zh) 嘧啶并-哒嗪酮化合物及其用途
NZ522226A (en) Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
CN101616667A (zh) 可用作激酶抑制剂的杂环酰胺化合物
Ruminski et al. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2 S, 5 R)-5-(hydroxymethyl)-1, 4-dioxan-2-yl) methyl)-2 H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis
CN101316829A (zh) 具有crth2受体活性的噁二唑衍生物
AU2219599A (en) Platelet adp receptor inhibitors
CA2269814A1 (en) 2-methoxyphenylpiperazine derivatives
CN101490061A (zh) 噻二唑化合物和其使用方法
Yang et al. Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation
Modica et al. Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands
US20040034012A1 (en) 1,4,5,6-Tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
CN109251187A (zh) 一种2-硝基苯基磺酰胺类衍生物、其制备方法和医药用途
CN102219759B (zh) 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
JP2003277263A (ja) 医薬組成物
HK1111414B (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
JPH03232885A (ja) キナゾリン誘導体およびその塩

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111414

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1111414

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100929

Termination date: 20120926